



NEWS RELEASE

FOR IMMEDIATE RELEASE

Contact: Ronald Trahan, APR, President, Ronald Trahan Associates Inc., +1-508-359-4005,x108

STENTYS joins Stent for Life Initiative to expand optimal heart attack treatment across Europe

PRINCETON, N.J., and PARIS, May 18, 2011 — **STENTYS S.A. ([STNT.PA](#))**, a medical technology company commercializing the world's first and only self-apposing stent to treat **Acute Myocardial Infarction (AMI)**, announced today that it has joined the Stent for Life (SFL) Initiative as a key industry partner.

The Stent for Life Initiative is a unique European platform for interventional cardiologists, government representatives, industry partners, patient groups and patients to work together and, by helping to shape health care systems and medical practices, ensure that the majority of patients with acute heart attack have equal access to the life saving indication of percutaneous coronary intervention (PCI) and stenting. The Initiative has been rolled out in 10 countries to date.

“There is irrefutable scientific evidence that revascularization with coronary stents in patients with acute myocardial infarction is life-saving: it not only reduces mortality but also reduces rates of non-fatal reinfarction when compared to the previous standard of care— pharmacological treatment,” said **Gonzague Issenmann, CEO and co-founder of STENTYS**. “We are extremely proud to contribute to the Stent for Life mission to increase patient access to this therapy.”

STENTYS recently announced that it has reached the mid-point of its international **APPOSITION III** study of its **Self-Apposing** Stent, with **250** patients now enrolled out of a total of **500**. The trial primary endpoint is Major Adverse Cardiac Events (MACE) at 12 months post-procedure.

AMI affects 100,000 people each year in France and an additional 900,000 people in the United States and represents an annual worldwide market of approximately \$2 billion.

About STENTYS

Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by **Jacques Séguin, M.D., Ph.D., (also founder of CoreValve, which was acquired by Medtronic)** and **Gonzague Issenmann**, STENTYS received CE-marking for its flagship products in 2010. Its **self-apposing** stent adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevents the **malapposition** problem associated with conventional stents. STENTYS has commenced marketing activities in several European countries.

About Stent for Life

The Stent for Life Initiative was launched by the coalition of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and EuroPCR in 2009. The Stent for Life Initiative mission is to improve the delivery of care and patient access to the life saving indication of primary percutaneous coronary intervention (p-PCI), thereby reducing the mortality and morbidity of patients suffering from acute coronary syndrome (ACS).

This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not been offered or sold in the United States and may not be offered or sold in the United States of America, except pursuant to a registration statement under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.

#####